Skip to Content
Merck
  • An overview of tubulin inhibitors that interact with the colchicine binding site.

An overview of tubulin inhibitors that interact with the colchicine binding site.

Pharmaceutical research (2012-07-21)
Yan Lu, Jianjun Chen, Min Xiao, Wei Li, Duane D Miller
ABSTRACT

Tubulin dynamics is a promising target for new chemotherapeutic agents. The colchicine binding site is one of the most important pockets for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. A large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. CBSIs have been modified as to chemical structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers. CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin. The present review is a synopsis of compounds that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.

MATERIALS
Product Number
Brand
Product Description

Colchicine, (European Pharmacopoeia (EP) Reference Standard)
Sigma-Aldrich
Colchicine, ≥95% (HPLC), powder
Sigma-Aldrich
Colchicine, BioReagent, suitable for plant cell culture, ≥95% (HPLC)